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Abstract We tested the hypothesis that stabilizing a-
helix of Epstein–Barr virus gH-derived peptide 11438 used
for binding human cells will increase its biological activity.
Non-stable a-helix of peptide 11438 was unfolded in an
entropy-driven process, despite the opposing effect of the
enthalpy factor. Adding and/or changing amino acids in
peptide 11438 allowed the designing of peptides 33207,
33208 and 33210; peptides 33208 and 33210 displayed
higher helical content due to a decreased unfolding entropy
change as was determined by AGADIR, molecular
dynamics and circular dichroism analysis. Peptides 33207,
33208 and 33210 inhibited EBV invasion of peripheral
blood mononuclear cells and displayed epitopes more
similar to native protein than peptide 11438; these peptides
could be useful for detecting antibodies induced by native
gH protein since they displayed high reactivity with anti-
EBV antibodies. Anti-peptide 33207 antibodies showed
higher reactivity with EBV than anti-peptide 11438 anti-
bodies being useful for inducing antibodies against EBV.
Anti-peptide 33210 antibodies inhibit EBV invasion of
epithelial cells better than anti-peptide 11438 antibodies.
Peptide 33210 bound to normal T lymphocytes and Raji
cells stronger than peptide 11438 and also induced apop-
tosis of monocytes and Raji cells but not of normal T cells
in a similar way to EBV-gH. Peptide 33210 inhibited the
monocytes’ development toward dendritic cells better than
EBV and peptide 11438. In conclusion, stabilizing the a-
helix in peptides 33208 and 33210 designed from peptide
11438 increased the antigenicity and the ability of the
antibodies induced by peptides of inhibiting EBV invasion
of host cells.
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Abbreviations
EBV Epstein–Barr virus
PBMCs Peripheral blood mononuclear cells
GM-CSF Granulocyte–monocyte colony stimulating
factor
RP-HPLC Reverse phase-high performance liquid
chromatography
CD Circular dichroism
TFE 2,2,2-Triﬂuoroethanol
DH Enthalpy change
DS Entropy change
DG Gibbs free energy change
Introduction
Epstein–Barr virus (EBV), one of the most common
worldwide human viruses, is capable of inducing infectious
mononucleosis (Henle et al. 1968) and it has also been
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nasopharyngeal carcinoma (Huang et al. 1974; Raab-Traub
et al. 1987), Burkitt’s lymphoma (De-The and Zeng 1982),
and the X-associated lymphoproliferative disease (Harada
et al. 1982). EBV is also critical in immune compromised
patients receiving allograft or having acquired immune
deﬁciency syndrome, sometimes leading to host death
(Montagnier et al. 1984; Pelicci et al. 1986; Yarchoan et al.
1986).
EBV can infect monocytes, B lymphocytes and epithe-
lial cells mainly through EBV proteins gp350/220 and
gp42/gH/gp25 (gp42/gH/gL) complex which binds to host
cell proteins CD21 (CR2), MHC class II and the integrins
avb6 and avb8 (Chesnokova et al. 2009;L i1997; Neme-
row et al. 1989; Spriggs et al. 1996; Tanner 1987; Wang
et al. 1998). The gH protein (also known as gp85) can be
used as an alternative EBV ligand in CD21 and MHC class
II-negative epithelial cells and is actively involved in virus
and cell membrane fusion (Miller and Hutt-Fletcher 1988;
Haddad and Hutt-Fletcher 1989; Molesworth et al. 2000;
Wang et al. 1998). The gH protein is part of a heterodimer
complex (gH/gL) which is highly expressed on EBV pro-
duced from B cells and the heterotrimer complex (gH/gpL/
gp42) which is highly expressed on EBV produced from
epithelial cells (Wang et al. 1998). The trimer:dimer ratio
is key for EBV cell tropism; EBV from B cells tends to
infect easily epithelial cells whereas EBV from epithelial
cells efﬁciently infects B lymphocytes (Borza and Hutt-
Fletcher 2002). EBV is not able to fuse with B cells or bind
to epithelial cells in the absence of the gH or when the
heterotrimer complex is blocked with an anti-gp42 mono-
clonal antibody (F-2-1), but does not affect EBV-binding to
B lymphocytes (Borza and Hutt-Fletcher 2002; Haddad and
Hutt-Fletcher 1989, 1988), indicating the importance of gH
protein in EBV attaching to epithelial cells and fusion to B
cells.
It has been also reported that EBV-gH/gL complex is
able to interact with monocyte cells. When these mono-
cytes were cultured with granulocyte–monocyte colony
stimulating factor (GM-CSF) and interleukin-4 (IL4) this
interaction was able of inhibit the development of mono-
cytes towards dendritic cells by delaying the down-regu-
lation of CD14 marker and by inducing apoptosis (Li et al.
2002).
There are two cell-binding regions identiﬁed in this
protein; peptides (11435 and 11438) from these regions
speciﬁcally bind to host cells and inhibit EBV invasion of
peripheral blood lymphocytes (PBLs) (Urquiza et al. 2004).
Antibodies induced by these peptides were also able of
inhibit EBV invasion of PBLs, but presented low reactivity
against EBV by ELISA. These suggest that lower biolog-
ical activity of peptides compared with the native protein is
due to high conﬁgurational entropy. Modiﬁcations in
amino acid sequences can diminish conﬁgurational peptide
entropy by stabilizing its structure. The aim of this work
was to increase the peptide’s biological activity by
changing or adding some amino acids that diminish pep-
tide’s entropy.
Materials and methods
Peptide synthesis
Peptides were synthesized by solid-phase multiple peptide
system (Houghten 1985; Jeener et al. 1979). MBHA resin
(0.7 meq/g); t-Boc amino acid, and low–high cleavage
techniques were used. Peptides were analyzed by MALDI-
TOF mass spectrometry and reverse phase-high perfor-
mance liquid chromatography (RP-HPLC) (data not
shown). Peptides were reconstituted in sterile PBS pH 7.4.
AGADIR analysis
Helical content of peptides were calculated using the pre-
diction algorithm developed by Serrano’s group (AGA-
DIR) with an amide group at the C-terminal and an acetyl
group at the N-terminal region. The conditions used were:
temperature at 278K, ionic strength 0.1 and pH 7.0
(Mun ˜oz and Serrano 1997).
Circular dichroism analysis
Circular dichroism (CD) spectra were made for peptides
11438, 33207, 33208 and 33210 to estimate a-helix content
percentage and stability. Peptides were prepared in aqueous
30% TFE solution at 100 lM concentration. CD spectra
were taken on a 1-cm-long quartz cell on a Jasco J-810
thermostated spectrophotometer (Provencher and Glockner
1981). CD spectra resulted from the average of four scans
obtained by collecting data at 0.1-nm intervals from 260 to
190 nm at 20C. The a-helical content was estimated from
the molar ellipticity at 222 nm by using the following
equation:
%a-helix¼ð ½H 222nm þ 3000Þ=39000
where [H] is molar ellipticity (Provencher and Glockner
1981).
The thermodynamic analysis of an a-helix unfolding/
folding transition was performed by Van’t Hoff analysis.
In brief, a-helix content percentage estimated from
absorption at 222 nm, at different temperatures (T), lead
to calculating afﬁnity constants (K) for unfolding folding
transition at these temperatures. The (1/T) versus Ln(K)
curve gave a straight line in which, according to the
following equation:
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The slope is unfold/fold transition enthalpy change over
R-constant and the intercept is unfold/fold transition
entropy change over R-constant.
Modeling and molecular dynamics of peptides
The peptide helices were built using the program
QUANTA based on primary sequence using the helical
angles phi -60 and -50 psi, the side chains were
accommodated by using the Karplus rotamer library in
order to reduce high-energy interactions that destabilized
the model. These molecules were submerged in a water
box containing 11 9 11 9 16 water molecules. Then
5,000 steps of minimization were performed by steepest
descendent at an initial temperature 100K and then
increased to reach the ﬁnal temperature of 310K. The
molecular dynamics was ran at a constant temperature,
pressure and number of molecules, using the program
CHARMM (http://www.charmm.org), the unfolding of the
peptide was followed by molecular dynamics during
200,000 steps of 0.01 ps each one. Data from energy,
structure and trajectory were collected every 500 steps. The
ﬁnal analysis was based on the structure and number of
hydrogen bonds that were present in the peptide over a
period of 100 ps by using distribution curves.
Immunization protocol
Two New Zealand rabbits were subcutaneously immunized
with 500 lg of peptides 11438, 332207, 33208, 33210 or
EBV physically mixed with 150 lg of T helper epitope
FISEAIIHVLHSR (Prieto et al. 1995) and emulsiﬁed with
250 ll Freund’s complete adjuvant (500 ll ﬁnal volume).
Then rabbits were boosted on days 20, 40 and 60, with the
same antigen dose but emulsiﬁed in Freund’s incomplete
adjuvant. Blood was drawn 20 days after the second and
third doses.
Rabbit antibody isolation
Rabbit sera were diluted four times with 60 mM acetate
buffer (pH 4.0); the pH was raised to 4.5 by adding NaOH
0.1 N. 25 ll/ml caprylic acid was added and stirred for
30 min. Samples were then centrifuged at 10,0009g for
30 min, and the supernatant was separated. A 1/10 volume
of 109 PBS was added to the obtained supernatant and the
pH adjusted to 7.4 with NaOH 0.1 N. The immunoglobulin
fraction was precipitated with 0.35 g/ml ammonium sulfate
overnight at 4C. The pellet was separated at 5,0009g for
15 min at 4C and suspended in PBS. The immunoglobulin
solution was extensively dialyzed with PBS. The isolated
protein concentration was determined by the Bradford test
(100–170 lg/ml) and antibody activity by ELISA (Delves
1997).
Antibodies reactivity detected by ELISA
ELISA-plates with 96-wells were coated with peptides
11438, 33207, 33208 or 33210, at different concentrations
(10–0.6 lg/ml) diluted in PBS and incubated overnight at
4C. Plates were then washed four times with PBS con-
taining 0.05% Tween20 (PBS-T). Non-speciﬁc binding
sites were blocked with 200 ll 4% non-fat dry milk in
PBS-T for 2 h at 37C. After washing as described above,
100 ll of rabbit sera serial dilution (1/100, 1/51,200) was
added and incubated for 1 h at 37C. After washing, per-
oxidase-conjugated anti-rabbit antibody (VECTOR) was
diluted 1:5,000 in blocking buffer and 100 ll was added to
each well. The plates were incubated for 1 h at 37C. After
washing, 100 ll peroxidase substrate (3,30,5,50-tetramethyl
benzidine-SIGMA) was added to the plates. To stop the
reaction, H2SO4 (0.1 N) was added to each well and
absorbance was measured at 420 nm. The assay was per-
formed in triplicate and considered valid only when the
triplicates’ coefﬁcient of variation was lower than 10%.
Antibody titers were calculated as the minimum dilution
at which the antiserum recognized the antigen.
PCR ampliﬁcation of EBV DNA
EBV-containing supernatant used for EBV and B lym-
phocyte interaction studies was obtained from the Ameri-
can Type Culture Collection (ATCC Catalogue number
VR-1492). DNA from normal PBMCs was obtained by
phenol–chloroform extraction and ethanol precipitation.
DNA was dissolved in 20 ll of TE buffer [10 mM Tris–
HCl (pH 8.0), 1 mM EDTA], 0.5 mg/ml ﬁnal concentra-
tion (Chen et al. 2002). PCR was performed in 20 llo f
reaction mixture containing 10 mM Tris–HCl (pH 8.3),
50 mM KCl, 1.5 mM MgCl2, and each of the following
200 lM deoxyribonucleotide triphosphate, 0.1–0.5 lgo f
template DNA, each primer at 0.5 lM, and 1.0 unit of Taq
polymerase. Previously reported primers (3) were used to
speciﬁcally amplify EBV DNA: 50-TTCATCACCGTCG
CTGACT-30 upstream sequence and 50-ACCGCTTA
CCACCTCCTCT-30 downstream sequence. These primers
speciﬁcally ampliﬁed a 300-bp DNA fragment from EBV
(?) cells (Raji or B95-8), but not EBV (-) cells (eryth-
rocyte fraction, or HeLa cells). PCR conditions consisted
of 35 cycles at 95C for 30 s, 55C for 30 s, and 72C for
30 s in a 9600 thermal cycler (PerkinElmer Life Sciences).
The ampliﬁed fragment was separated on 2.0% agarose
gels; the PCR product was visualized on a Molecular
Imager FX (Bio-Rad).
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Serial dilutions of anti-peptide sera were incubated with
EBV for 30 min at 37C. Then 5 9 10
3 HEK293 cells
were added in a ﬁnal volume of 40 ll and incubated for 4 h
at 37C. Cells were washed twice with HBSS 19 and
heated at 100C for 10 min. DNA was suspended in 20 ll
of ultra pure water and 2 ll were used for PCR ampliﬁ-
cation as described above.
EBV infectivity inhibition assay
PBMCs or HEK 293 cells were culture at a density of
2 9 10
5 cells/100 llinRPMI1640,supplementedwith10%
heat-inactivated serum, 100 U/ml penicillin, 100 lg/ml
streptomycin, 0.4 lg/ml cyclosporine A, and 5 mM CaCl2
andincubatedwith30 llEBV-supernatantfor30 minat37C
in5%CO2 atmosphere.Then70 ll RPMI-1640 mediumwas
addedandthesampleswereincubatedfor16 hat37Cin5%
CO2 atmosphere. After incubation, cells were washed three
times with RPMI-1640 medium (FBS free). The peptide’s
effectonEBV-interactionwithPBMCsorHEK293cellswas
determinedbypre-incubatingthesecellswith27,13,or7 lM
ofeachpeptidefor15 minat37Cimmediatelyprecedingthe
EBV-interaction with host cells (Urquiza et al. 2004).
Peptide’s binding assay
PBMC from a normal donor and Raji and Ramos cell lines
were incubated with peptides 11438, 33207, 33208 or 33210
at different concentrations (1, 3 or 10 lM) in FACS buffer
(PBS,BSA1%,sodiumazide0,05%).After1 hofincubation
at 4C, cells were washed and incubated with anti-peptide
serum produced in rabbits at a 1/200 dilution for 40 min at
4C. Only PBMCs were additionally stained with antibodies
anti CD3-PerCP, CD19-PE and CD14-APC conjugated anti-
bodies. Unbound antibodies were washed and cells were
incubated with mouse anti-rabbit IgG-FITC and propidium
iodidetoexcludedeathcells.After40 minofincubation,cells
were washed and resuspended in 200 lLo fF A C Sb u f f e r .
Samples were run in a FACScan and data analysis was per-
formedbyusingCellQuestsoftware.Todeterminethepeptide
binding, ﬁrst we calculated the mean ﬂuorescence intensity
ratio (MFIR) of the cells incubated with the peptide and its
anti-peptide rabbit-serum divided by the mean ﬂuorescence
intensity of the cells incubated only with the anti-peptide
rabbit-serum. Then, we calculated the percentage of binding
based on 11438-peptide binding as 100%.
Human monocyte isolation
PBMCs were obtained from healthy donor, collected in
heparin-treated sterile tubes by sedimentation on Ficoll-
Hypaque gradients. PBMCs thus obtained were washed
three times with RPMI-1640, spun at 3009g for 7 min at
room temperature. Cell count and viability was determined
by trypan blue staining (GIBCO). 2 9 10
6 cells/ml were
cultured in RPMI 1640 medium supplemented with 10%
heat-inactivated FBS, 100 U/ml penicillin, 100 lg/ml
streptomycin and were allowed to adhere to a 24-well tis-
sue culture plate for 4 h at 37C with 5% CO2 atmosphere.
For removing non-adherent cells, conﬂuent monolayers
were washed once with RPMI 10% FBS.
EBV invasion
EBV used for studies was obtained from the American
Type Culture Collection (ATCC catalogue no. VR-1492).
Conﬂuent monolayers of cells were cultured with 7.2 nM
recombinant GM-CSF (Biosource) and 6.7 nM recombi-
nant IL4 (Biosource). These cells were culture in presence
of 40 ll of EBV (1009) or 10.4 lM of peptide (11438,
33207, 33208 or 33210) and incubated for 3 days at 37C
with 5% CO2 atmosphere. Monocytes were harvested with
PBS–EDTA 0.5 nM by ﬂushing three times and washed
twice with PBS–EDTA 0.5 nM, spun at 2,000 rpm for
5 min and stained with CD14-FITC conjugated (Pharmi-
gen) 1/100 dilution for 20 min. Cells were washed once
with PBS–EDTA 0.5 mM and suspended in 200 llo f
PBS–EDTA. Fluorescence intensity was monitored with a
FACScan ﬂow cytometer (Becton–Dickinson). This
experiment was performed by duplicated and tested with
six different volunteers given similar results.
Peptide’s cytotoxicity assay
PBMC and Raji cells were culture with peptides 11438,
33207, 33208 or 33210 at different concentrations (1, 3 or
10 lM) in RPMI supplemented with FBS 10%. After 3 h
of incubation at 37C, cells were washed and resuspended
in Annexin buffer 1X, Annexin V FITC conjugated and PI
for 30 min at 4C. PBMCs were additionally stained with
anti-CD3 and anti-CD14 antibodies. Then, cells were sus-
pended in 100 ll of Annexin buffer 19 and run in a
FACScan.
Results
Peptides having theoretically more stable a-helix
were designed from peptide 11438 by using AGADIR
Peptide 11438 from EBV-gH contains a host human cell-
binding sequence; this peptide is able to inhibit EBV
invasion of B lymphocytes and to induce antibodies rec-
ognizing native protein; but its biological activity is lower
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region, which has been predicted having a high content of
a-helix as determined by GOR software (Garnier et al.
1996) and as it has previously been published (Omerovic
et al. 2005). The CD spectrum of peptide 11438 dissolved
in PBS with 30% TFE displayed two minimum adsorptions
at 208 and 222 nm that is characteristic of a-helix
(Fig. 1b). The peptide’s helical content (determined by
using absorption at 222 nm) increased from 5.02 to 24.55%
in 0 and 30% of TFE, respectively (Table 1). This indi-
cated that peptide 11438 tended to be an a-helix but this
structure was not stable in aqueous solution and was easily
distorted.
The theoretical helical content calculated for peptide
11438 in pH 7.0, ionic strength 0.1 and at 278K temper-
ature was 0.83% by using the approach developed by
Serrano’s group (AGADIR analysis) (Bax and Davis 1985;
Houghten 1985; Rance et al. 1983; Tam et al. 1983). N-
terminal or C-terminal truncated peptides were analyzed by
the same approach for determining the ability of each
amino acid from peptide 11438 sequence to stabilize or
distort the a-helix structure. It was found that peptide’s
helical content was very low in part due to
4P and beta-
branched residues
14VTMT
17 that could distort the helix at
the N-terminal and C-terminal region, respectively (data
not shown). Taking into account this analysis, the
5NLKDMFSRA
13 sequence was used as template for
designing new peptides that in theory could display a
higher helical content than native sequence. Three different
groups of peptides were designed either by adding amino
acids at the C-terminal (Group 1), at the C-terminal after
13Ala (Group 2) or at the N-terminal before
5Asn (Group 3)
for inducing one theoretical a-helix turn; in other words
four residues having high probability of building one turn
of a-helix (and also create intra-peptide interactions to
stabilize the helix) were included considering that the most
difﬁcult part of a-helix folding process is the induction of
the ﬁrst a-helix turn. Basic amino acids, Arg and Lys, were
added at the C-terminal and acid amino acids Asp and Glu
were added at the N-terminal to stabilize the a-helix dipole
taking into account that the C-terminal region and the N-
terminal region of the a-helices are often capped with a
positively charged amino acid, such as lysine and by a
negatively charged amino acid, such as glutamic acid,
respectively, in order to neutralize this helix dipole.
The designed peptide sequences having the highest
calculated percentage of helical content appear in Fig. 1a.
Only one peptide sequence from each group was selected
for synthesis. These were NLKDMFSRAVTMTAASRK-
RAE (named peptide 33207); FVFNLKDMFSRANRK
RKA, (named 33210) and MEDDYNLKDMFSRAVTM
(named peptide 33208), were selected from the ﬁrst, sec-
ond and third group, respectively. Theoretical saline
bridges were added at the N-terminal (3D–7K) in peptide
33208 or C-terminal (21R–25E) in peptide 33207. We
expect that the modiﬁed regions in peptides 33207, 33208
and 33210 will be non-immunogenic considering that most
of these regions are built with charged amino acids that in
general have been reported not involved in interactions
with antibodies because the energetic cost for binding.
The theoretical a-helix of peptides 33207, 33208
and 33210 were more stable than the helix of peptide
11438 as determined by molecular dynamics
The a-helix of peptides 11438, 33207, 33208 and 33210
were built hydrated and minimized at 310K by using
QUANTA program; then the a-helix stability was studied
Fig. 1 Helical content and circular dichroism analysis performed in
EBV-gH-derived peptides. a Peptide 11438 was modiﬁed by adding
or deleting amino acids at C- and N-terminal regions and the helical
content was calculated by AGADIR analysis. The sequence of peptide
11438 is shown in the gray bar. b Circular dichroism of peptides
selected from each group (33207, 33208 and 33210 from groups 1, 2
and 3, respectively) and peptide 11438 were dissolved in PBS with
30% TFE; the spectra were made on a JASCO spectrometer. The X-
axis shows wavelength in nm and the Y-axis molar ellipticity per
residue
Table 1 Helical content of peptides 11438 and its analogs
Peptide % Helical content
0% TFE 5% TFE 30% TFE
11438 5.02 5.34 24.55
33207 2.96 2.96 10.75
33208 9.86 11.38 40.39
33210 6.48 7.73 27.63
a-Helix peptides designed from EBV-gH protein 1511
123by molecular dynamics using CHARMM, quantifying the
mean number of hydrogen bonds that remains in the a-
helix at 0.0, 0.5, 1.0, 1.5 and 2.0 ns during the molecular
dynamics of the peptide in water at 310K. The a-helix of
peptide 11438 presented 11 mean hydrogen bonds at 0 ns;
the helix of this peptide unfold rapidly presenting 4 mean
hydrogen bonds at 0.5 ns and this helix was completely
unfolded at 1 ns. The helix of peptide 33207 presented 13
mean hydrogen bonds at 0.0 ns; this helix was very stable
showing that at 2.0 ns remains 8 mean hydrogen bonds.
The helix of peptide 33208 presented 8 mean hydrogen
bonds at 0.0 ns; this helix begins to unfold from the N-
terminal region; at 1.0 ns it displayed 6 mean hydrogen
bonds and at 2.0 ns displayed 3 mean hydrogen bonds. The
helix of peptide 33210 presented 9 mean hydrogen bonds at
0.0 ns; this helix began to unfold from the N-terminal
region displaying 6 mean hydrogen bonds at 1.0 and at
2.0 ns displayed 5 mean hydrogen bonds. These data
showed that a-helix of peptides 33207, 33208 and 33210
unfold slowly compared with peptide 11438 suggesting
that a-helix of peptides 33207, 33208 and 33210 were more
stable than the a-helix peptide 11438 (Fig. 2).
Circular dichroism showed that peptides 33208
and 33210 displayed more stable a-helix than peptide
11438 due to lower unfolding entropy change
Peptides 11438, 33207, 33208 and 33210 were synthesized
andanalyzedbyCDin0,5and30%TFEat25C;thehelical
content was determined by using absorption at 222 nm
(Fig 1b). The four analyzed peptides increased helical con-
tent in line with increased TFE concentration. Peptides
33208 and 33210 displayed a higher helical content than
peptide 11438 in 0, 5 and 30% TFE. On the contrary peptide
33207 presented a lower helical content than native peptide
11438 (Table 1). The 222 nm absorption in CD spectra at
differenttemperatureswasusedfordeterminingequilibrium
constants (Ke) of folding/unfolding reaction considering
11438
33207
33208
33210
0 ns 2 ns
# of Hydrogen Bonds
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e
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# of Hydrogen Bonds
B A
0
0,06
0,12
0,18
0,24
02468 1 0 1 2 1 4
0
0,25
0,5
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1
02468 1 0 1 2 1 4
0
0,08
0,16
0,24
02468 1 0 1 2 1 4
0
0,08
0,16
0,24
02468 1 0 1 2 1 4
0
0,08
0,16
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02468 1 0 1 2 1 4
0
0,25
0,5
02468 1 0 1 2 1 4
0
0,1
0,2
0,3
02468 1 0 1 2 1 4
0
0,1
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0,3
02468 1 0 1 2 1 4
Fig. 2 Molecular dynamics performed in peptides 11438, 33207,
33208 and 33210. The a-helix of peptides 11438, 33207, 33208 and
33210 were built by using Quanta. After these peptides were hydrated
and minimized the molecular dynamics were run during 2 ns at 310 K
by using CHARMM. a Mean frequency of hydrogen bonds that are
present in the peptide structure at 0.0 ns. On the right side are shown
the ribbon structures acquired by these peptides during the molecular
dynamics, which were built by using VMD program. In b is shown
the same as in a but at 2 ns
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conformation and fold stage a-helix peptide conformation.
DG of folding–unfolding was determined from DG =
-RTLn(Ke); DH and DS of folding/unfolding reaction were
determinedfromKeatdifferenttemperaturesbyusingVan’t
Hoff’s equation (Table 2). Helical content for these four
peptides(11438,33207,33208and33210)varied linearlyin
the studied temperature range, having square linear corre-
lation coefﬁcients between 0.93 and 1.00, displaying a
negative slope and thereby showing that the a-helix in these
peptides unfolded when temperature was increased. Ln(K)
versus 1/T curve for these four peptides displayed negative
slopes with square linear correlation coefﬁcients between
0.94 and 0.99 supporting Van’t Hoff’s analysis (Table 2).
Most of the molecules or the sequence of these four peptides
tend to stay in an unfolded state (random conformation),
according to DG determined above, but the helical content
and the stability of the helix of peptide 33208 (DG =
-1.02 kJ/mol)and33210(DG =- 2.40 kJ/mol)washigher
than peptide 11438 (DG =- 2.72 kJ/mol); on the contrary,
the helical content and the helix stability of peptide 33207
(DG =- 5.33 kJ/mol) was lower than peptide 11438. The
helix ofthesepeptides tend to unfold due toa higher entropy
of the unfolded state than the folded state; being higher for
peptide 11438 (TDS = 15.48 kJ/mol) than peptide 33207
(TDS = 10.973 kJ/mol), peptide 33208 (TDS = 10.973 kJ/
mol) and peptide 33210 (TDS = 13.43 kJ/mol). On the
contrary, the enthalpy change opposes to unfolding of the
helixofthesepeptides(DHbetween5.64and12.76 kJ/mol).
The higher a-helix stability of the peptides 33208 and
33210 compared with peptide 11438 was due to lower
entropy change of unfolding in spite of having lower
enthalpy change of unfolding than peptide 11438. On the
contrary, the lower a-helix stability of the peptide 33207
than peptide 11438 is due to a lower enthalpy change of
unfolding (DH = 5.64 kJ/mol) in spite of a lower entropy
change of unfolding compared with peptide 11438. These
data indicate that the modiﬁed peptides 33208 and 33210
were more prone to state as a-helix than native peptide
11438 as a consequence of minor entropy change in fold–
unfold transition.
Peptides 33207, 33208 and 33210 displayed epitopes
with higher reactivity with anti-EBV antibodies but no
higher immunogenicity than peptide 11438
In order to determine whether or not amino acid changes on
these peptides modiﬁed the epitopes that interact with the
antibodies induced by EBV, the reactivity of peptides
11438, 33207, 33208 and 33210 with anti-EBV was
determined by using ELISA. The antibodies induced by
EBV were able to recognize peptides 33207, 33208 and
33210 with antibody titers of 25,600, 51,200 and 12,800,
respectively, having higher reactivity than with peptide
11438 which showed an antibody titer of 6,400 (Fig. 3a).
Anti-EBV antibodies did not recognize irrelevant peptide
(data not shown).
Taking into account that analog peptides displayed
higher reactivity with anti-EBV antibodies than peptide
11438, we were interested in determining how strong the
reactivity of the antibodies induced by analog peptides with
Table 2 a-Helix thermodynamic folding parameters of peptide
11438 and its analogs
Peptide DG (kJ/mol) DH (kJ/mol) TDS (kJ/mol) R
2
11438 -2.72 12.76 15.48 0.99
33207 -5.33 5.64 10.97 0.93
33208 -1.02 9.80 10.82 0.97
33210 -2.40 11.04 13.43 1.00
Fig. 3 Antigenicity and immunogenicity of peptides 11438, 33207,
33208 and 33210. Rabbits were immunized with EBV, 11438, 33207,
33208 or 33210. After three immunizations polyclonal serum was
obtained and tested by ELISA. a Anti-EBV antibodies were tested for
their reactivity against peptides to evaluate peptides’ antigenicity.
b Reactivity of anti-peptides antibodies was tested against EBV to
evaluate peptide’s immunogenicity. PI pre-immune sera
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123EBV is compared with the reactivity of peptide 11438. The
immunogenicity of peptides was determined by the reac-
tivity of antibodies induced by these peptides in recog-
nizing EBV. Polyclonal sera were obtained by immunizing
rabbits with peptides 11438, 33207, 33208 or 33210 as
described in ‘‘Materials and methods’’. The titers of the
polyclonal sera against the respective peptide were higher
than 100,000 (data not shown). Then the polyclonal serum
was tested for its reactivity against EBV. The antibodies
induced by peptides 11438 and 33208 presented similar
reactivity against EBV with antibody titer of 800, anti-
bodies induced by peptide 33210 presented lower reactivity
with antibody titer of 200 and anti-33207 antibodies pre-
sented a higher reactivity in recognizing EBV with anti-
body titer of 1,600 (Fig. 3b).
Peptides 11438, 33207, 33208 and 33210 inhibited
EBV invasion of host cells in vitro
It has been previously reported that peptide 11438 is able to
inhibit EBV invasion of PBMCs (Urquiza et al. 2004). We
tested whether or not the analog peptides designed were
able to inhibit virus invasion. The results showed that
analog peptides 33207, 33208 and 33210 were able to
inhibit EBV invasion of PBMCs in a similar manner than
peptide 11438 in vitro at 27 lM but not at 13 or 7 lMa s
determined by PCR. Additionally taking into account that
gH binds to epithelial cells, we tested the ability of these
peptides in inhibiting the invasion of EBV by HEK293
cells. Peptide 11438 inhibited at all the concentrations
tested (27, 13 and 7 lM). Peptides 33207 and 33210
inhibited at 27 and 13 lM, and peptide 33208 inhibited
only at 27 lM. This indicates that sequence modiﬁcations
performed in peptides 33207, 33208 and 33210 did not
alter the ability of these peptides to block EBV invasion of
PBMCs but there was a decrease in the ability of analogous
peptides to block invasion of HEK293 cells (Fig. 4a).
EBV-binding inhibition assay was not performed using
the gH protein directly considering that we do not have a
quantitative test for detecting EBV-binding to host cells or
the gH-complex.
Anti-peptide 33210 antibodies inhibit EBV invasion
of epithelial cells better than anti-peptide 11438
antibodies
The capability of anti-peptide antibodies in inhibiting EBV
invasion of epithelial cells was determined considering that
gH protein can be used as an alternative EBV ligand in
epithelial cells. HEK293 cells were selected for these
experiments taking into account that previously it was
demonstrated that EBV infects this cell line (Fingeroth
1999). EBV was incubated with serial dilutions of anti-
peptide antibodies then added to HEK cells; the EBV-
infected cells were detected by PCR. It was found that anti-
peptide antibodies induced by 11438, 33207 and 33208
inhibited the EBV invasion of these cells up to rabbit-
serum dilutions of 10
-3; anti-peptide 333210 antibodies
inhibited up to serum dilution of 10
-4 (Fig. 4b.). These
results indicate that analog peptides 33207, 33208 and
33210 contain critical epitopes for induction of neutralizing
antibodies; additionally, peptide 33210 induced more
potent anti-EBV neutralizing antibodies than peptide
11438.
Peptide 33210 showed higher binding activity
to PBMC, Ramos and Raji cells than peptide 11438
Taking into account that peptide 11438 sequence belongs
to the gH binding region we were interested in determining
the binding of these peptides to different type of cells.
Peptide 11438 bound to PBMC, Ramos and Raji cells as
detected by ﬂow cytometry. Taking peptide 11438 binding
to these cells as 100% it was found that peptide 33210
displayed between 150 and 250% higher binding activity to
PBMC and Raji cells than peptide 11438; it was not pos-
sible to detect differences in the binding of peptides 11438,
33207 and 33208 to these cells as determined by ﬂow
cytometry, suggesting that peptides 11438, 33207 and
33208 have a lower binding afﬁnity than peptide 33210.
The analysis performed in PBMC showed that peptide
B
a11438
a33207
a33208
a33210
10-1 10-2 10-3  10-4 10-5 10-6
Serum dilution
A
1    2     3 1    2    3 1     2    3 1    2    3
11438 33207 33208 33210
PBMCs
HEK293 
cells
Fig. 4 Effect of peptides and anti-sera of peptides 11438, 33207,
33208 and 33210 in EBV invasion of host cells. a PBMCs and
HEK293 cells were treated with EBV and peptides 11438, 33207,
33208 or 33210 at different concentrations: 1 27 lM, 2 13 lMo r3
7 lM. After the incubation period DNA was isolated and PCR
ampliﬁcation of an EBV DNA fragment was performed. b Activity of
anti-peptide sera at different dilutions in neutralizing EBV invasion of
HEK293 cells
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12333210 preferentially bound to T cells (CD3?) (Fig. 5a)
compared to B cells (CD19) or monocytes (CD14). Inter-
estingly, peptide 33210 increased CD3 positive cells in
vitro.
Peptide 33210 inhibited the development of monocytes
towards dendritic cells better than EBV
We asked whether gH-derived peptides inhibit the devel-
opment of dendritic cells from precursor monocyte in the
same manner as gH protein does as described by Li et al.
(2002). Monocytes in presence of granulocyte–monocyte
colony stimulating factor (GM-CSF) and interleukin-4 (IL-
4) mature towards dendritic cell; however, if these mono-
cytes are simultaneously incubated with EBV they do not
mature to dendritic cells as determined by the persistent
expression of CD14 surface marker due to the interaction
of gH with monocyte surface. GM-CSF and IL-4 exposed
monocytes were incubated with peptides 11438, 33207,
33208, 33210 or EBV to determine their capacity of reg-
ulating CD14 surface marker (detected by FACS analysis).
These cells in presence of EBV displayed 62% more CD14
positive cells than non-EBV-exposed cells peptides; in
presence of peptides 11438, 33207 or 33208 displayed
14.9, 27 or 13.5% more CD14 positive cells; respectively.
Interestingly, these monocytes in presence of peptide
33210 showed 89.2% more CD14 positive cells than non-
EBV-exposed cells and higher than native peptide 11438 or
EBV, indicating that this peptide displayed a better effect
on regulation of CD14 surface marker than peptide 11438
or EBV (Fig. 5b). In addition, it was determined that
peptide 33210 induces IL12p70 production in monocytes
cultured with GM-CSF and IL4 but not without these
cytokines (personal communication).
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Fig. 5 Capacity of peptides 11438, 33207, 33208 and 33210 to bind
to PBMCs, Raji and Ramos cells, their effect in CD14 marker on
dendritic cells and apoptosis in T cells, monocytes and Raji cells. a
The capacity of peptides to bind to normal T cells, Raji and Ramos
cells was tested by using ﬂow cytometry. The percentage of binding
compared with peptide 11438 was calculated as described in
‘‘Materials and methods’’. b CD14 surface expression on monocytes
exposed to GM-CSF and IL4 and incubated with EBV, peptides
11438, 33207, 33208 or 33210. The histogram data represents a
typical example of cells not exposed to EBV or peptide (thick line)
and exposed (dark line) to: a EBV, b peptide with similar effect to
EBV (33210), c peptide without effect (33207). Number of CD14
positive cells shown on the right side. c Effect of peptides in apoptosis
of PBMCs and Raji cells at 10 lM concentration. The percentage of
apoptotic cells was determined by staining with Annexin V and PI.
NT non-treated samples
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123Peptide 33210 induced apoptosis in Raji and monocytes
but not in T cells
Taking into account that peptide 33210 was able to bind
strongly to T cells and was able to inhibit the development
towards dendritic cells, we were interested in its effect on
survival or death of these cells as has been described for
EBV (Li et al. 2002). Peptides 11438, 33207, 33208 and
33210 were incubated with PBMCs and Raji cells as a
control, at different concentrations. The induction of
apoptosis was detected by the staining with Annexin V, PI,
CD5 and CD14. The result showed that peptide 33210
induced apoptosis in monocytes and Raji cells but not in
normal T cells (55, 38 and 17%, respectively) at a con-
centration of 10 lM (Fig. 5c).
Discussion
Peptide 11438 from EBV-gH host cell-binding region
inhibits EBV invasion of PBMCs, it is recognized by anti-
EBV antibodies and is also able to induce antibodies rec-
ognizing EBV and EBV-infected cells (Urquiza et al.
2004). This peptide displayed a CD spectrum characteristic
of an a-helix structure in 30% TFE, which decreased when
TFE concentration was lowered, indicating that this
structure was not stable. The aim of this work was to sta-
bilize 11438 peptide’s a-helix and to determine the effect
on its biological activity. Taking into consideration that
there is a signiﬁcant opposing entropy factor in interactions
involving peptides (due to high peptide chain mobility) that
induce high conﬁgurational peptide entropy, our approach
lies in reducing conﬁgurational peptide’s entropy by
changing some amino acids to stabilize the a-helix and
restrict the structures it can acquire in solution.
Peptide 11438 displays low helix stability as a result of
high positive unfolding entropy change, suggesting a
higher molecular disorder in unfolded than in folded state.
The helical region of peptide 11438 was located in
NLKDMFSRA sequence and very likely the N- and C-
terminal regions are not part of the helix; the peptide helical
content could be increased by adding basic residues at the
C-terminal, probably by stabilizing helix dipole as predicted
by AGADIR analysis. The helical content could not be
increased by adding residues at the N-terminal because of
the presence of 4Pro. On the contrary, the change of 4Pro,
insertion of acid residues or the deletion of the residues
preceding 4Pro, increased its helical content by stabilizing
the helix dipole. This resulted in the design of analog pep-
tides 33208 and 33210 displaying an a-helix more stable
than peptide 11438 as predicted by using AGADIR and
moleculardynamicanalysisanddeterminedbyCDanalysis.
In addition, unfolding of these helices was slower than
peptide 11438 according to molecular dynamic analysis.
The higher helix stability of peptides 33208 and 33210
was due to a lower unfolding entropy change probably
because these peptides in the unfolded state displayed a
lower conﬁgurational entropy than peptide 11438 in spite of
the fact that unfolding enthalpy change (the energy used for
breaking the hydrogen bonds) that stabilizes the helices was
decreasedin peptides 33208 and 33210. On the contrary, the
lower helix stability of peptide 33207 than peptide 11438,
was due to a lower unfolding enthalpy change despite the
lower unfolding entropy change. This result showed that
some a-helix stabilizing interactions were lost in peptide
33207 and could involve hydrophobic interactions mediated
bytheresiduesYFV;alsothatpeptide33207intheunfolded
state displays intra- and/or inter-molecular interactions that
stabilize the unfolded state that are not included in the
AGADIR calculation. The theoretical a-helix of peptide
33207 was very stable by molecular dynamics contrary to
the low helical content determined by CD; taking into
account that CD detects the mean peptide’s structure in
equilibrium a possible explanation could be that helix of
peptide 33207 unfolds slowly as determined by molecular
dynamicsbutalsofoldsveryslowlyinsuchwaythatmostof
the peptide molecules are in an unfolded state.
The biological activity of these peptides in comparison
with the native protein present in EBV was tested in the
following manner: (1) the ability of anti-EBV sera in rec-
ognizing peptides and the ability of anti-peptide sera to
bind to EBV; (2) the ability of each peptide and its anti-
sera to inhibit EBV invasion of host cells; (3) the cell-
binding activity of the peptide analogs on Raji, Ramos and
PBMCs; (4) the ability of peptides to mimic EBV inter-
action with monocytes by inhibiting its development into
dendritic cells; (5) the ability to mimic EBV infection by
inducing monocyte apoptosis.
Anti-EBV antibodies showed a higher reactivity against
analog peptides 33207, 33208 and 33210 than peptide
11438 suggesting that analog peptides have more similar
epitopes to native protein than epitopes on peptide 11438.
The higher anti-EBV reactivity with peptides 33207 and
Y F V P N L K D M F S R A V T M T A A S
R K R A E 
M E D D Y  
F                                 N R  K R K 
Peptide                    Amino acid sequence
11438
33207
33208
33210
Fig. 6 Representation of peptide 11438 regions and its analogs
related to their biological activity. We have found different regions
that are important for the binding to the cells (blue-NLKDMFSRA),
for keeping the a-helix structure (green-YFVP) and for the interaction
with the anti-EBV antibodies (red-NLKDMFSRA)
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12333208 than with peptide 11438 strongly suggests that
epitope recognized by anti-EBV antibodies is more
accessible considering that the EBV-sequence presented in
those peptides is contained in peptide 11438. Additionally
the reactivity of anti-EBV antibodies against 33208 was
higher than with 33207, despite its sequence being partially
contained in peptide 33207; this may be due to its higher
helical content, which is three times higher than in peptide
33207. The lower reactivity of anti-EBV antibodies with
peptide 33210 (compared with 33207 and 33208 peptides)
could be due to the lower helical content of peptide 33210
and the absence of the VTM sequence, which seems to be
part of the epitope recognized by anti-EBV antibodies.
All these results suggest that there are B cell epitopes
recognized by anti-EBV antibodies in the helical and non-
helical part of these peptides. Moreover, the epitopes on the
analog peptides recognized by these antibodies have a
more similar structure to native protein than epitopes on
peptide 11438, especially peptide 33208 that displayed the
highest helical content and showed the highest reactivity
with anti-EBV antibodies. Peptide 33208 could be very
helpful for detecting anti-gH antibodies induced by intact
EBV.
On the other hand, all these monomeric peptides
induced anti-peptide antibodies. Anti-peptide 33207 anti-
bodies showed the highest reactivity with EBV by ELISA
in spite of the fact that this peptide displayed the lowest
helical content, suggesting that the epitopes inducing these
antibodies were located in the non-helical region (con-
taining high proportion of b-branched amino acids missing
or modiﬁed in peptides 33208 and 33210). The low reac-
tivity of the anti-peptide 33210 antibodies with EBV sug-
gests that the VTM region is very important for the
induction of antibodies having cross reactivity with EBV.
This region could be exposed in peptide 33207 due to the
presence of positively charged amino acids (RKRAE) in
the C-terminal region. Although this region is also present
in peptide 11438, it could be buried by turn formation and
hydrophobic interaction with C-terminal region according
to the molecular dynamic analysis. These results show that
peptide 33207 would be useful for inducing antibodies that
recognize not only EBV infected cells but also EBV intact
particles, and also, to study the interaction of gH with host
cells.
Anti-peptide antibodies were capable of inhibiting the
EBV invasion of epithelial cells, anti-peptide 33210 anti-
bodies being ten times stronger than the other anti-peptides
antibodies in spite of its low reactivity with EBV. This
suggests that antibodies induced by peptide 33210 recog-
nized a more critical epitope for EBV invasion that prob-
ably is located in its helical region. This is also supported
by the fact that peptide 33210 displayed the highest bio-
logical activity.
We tested the ability of 11438 analogous peptides in
blocking EBV invasion of PBMCs as previously
reported(Urquiza et al. 2004); but taking into account that
EBV can bind and invade those cells using other proteins
such as gp350, we also used epithelial cells (HEK293)
(Fingeroth 1999) where gH plays a critical role for EBV
invasion. All analogous peptides were able to inhibit EBV
invasion of PBMCs and HEK293 at high concentrations
(27 lM). Only peptide 11438 inhibited EBV invasion of
HEK293 at low concentrations (7 lM) suggesting that
amino acids involved in this interaction are contained in
the sequence NLKDMFSRA, which were affected by the
changes made at the C and N-terminal in analogous
peptides.
On the other hand, it was found that peptide 33210 was
able to bind normal T cells and Raji cells (B cell line
derived from Burkitt lymphoma) which could be mediated
by a receptor that is present on both cells or T cell proteins
that are aberrant expressed on B cells (Raji cells) as has
been described in chronic lymphocytic leukemia (Steven-
son and Caligaris-Cappio 2004).
gH protein inhibits development towards dendritic cells
of monocyte cultured with GM-CSF and IL-4. This process
can be followed by detecting changes in CD14 expression
because this protein is down regulated or disappears when
monocytes mature to dendritic cells. Investigating the
peptide 33210 effects on the inhibition of the monocyte
development towards dendritic cells, it was found that this
peptide induced apoptosis of monocytes, as it was previ-
ously described for EBV (Li et al. 2002) but did not induce
apoptosis in normal T cells (to which it binds). The
mechanism involved in the apoptosis of monocytes could
be due to a direct effect of this peptide or an indirect effect
in which T cells may play a role. The better understanding
of the mechanisms involved in this interaction requires
further studies.
The biological activity of peptide 11438 that depends on
direct binding to cells was not modiﬁed in peptides 33207
and 33208 suggesting that the residues YFVP and TAAS
from N-terminal and C-terminal regions, respectively, and
the helical content of this peptide is not critical for this
biological activity. The higher biological activity of pep-
tide 33210 than peptides 11438, 33207 and 33208 suggests
that the VTM residues, missing in peptide 33210 could be
critical for modulating its activity and/or the sequence
added to C-terminal increased its biological activity by
inducing additional contacts that make the peptide inter-
action stronger with the cell (Fig. 6).
The changes performed on peptide 11438 decreased the
change in unfolding entropy that resulted in higher a-helix
stability of peptides 33208 and 33210. However, drastic
decreases in unfolding enthalpy change resulted in an
opposite effect by decreasing the a-helix stability as it was
a-Helix peptides designed from EBV-gH protein 1517
123shown in peptide 33207. Interestingly the biological
activity was modulated by these changes that are not nec-
essarily associated with the helical content. The increase in
the helix stability increased the reactivity with anti-EBV
antibodies as was seen in peptide 33208; it also showed
that anti-peptide antibodies (peptide 33210) directed
towards the a-helix were able to neutralize the EBV
infection to host cells.
Interestingly, we have designed peptide 33210 which
presented the highest binding activity, induction of apop-
tosis in monocyte and the arrest of maturation of dendritic
cells.
In general, these results showed that it is possible to
modulate not only the antigenicity and immunogenicity but
also the biological activity of peptide 11438 by modifying
the a-helix stability and the amino acid sequence. Peptides
33207, 33208 and 33210 will be useful to understand the
mechanism behind the molecular interactions between the
cells and gH.
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